- Eli Lilly unveils direct consumer sales for its weight loss drug, Zepbound, with pricing options under $500 monthly.
- Analysts predict a 18.10% potential upside for Eli Lilly stock price with a one-year target.
- Current consensus from brokerage firms rates Eli Lilly as "Outperform."
Eli Lilly's Direct Consumer Initiative
Eli Lilly (NYSE: LLY) is taking a strategic step forward by making the two highest doses of its weight loss medication, Zepbound, available directly to consumers via its LillyDirect platform. Starting in July, healthcare professionals will be able to prescribe these injectable solutions, which are affordably priced at $499 or less per month. Shipments are set to commence in August, presenting a significant development for both the company and weight management therapy options.
Wall Street Analysts' Forecast for Eli Lilly
Wall Street analysts have projected a diverse range of one-year price targets for Eli Lilly and Co (LLY, Financial), with 26 analysts participating in the analysis. The average target price is set at $967.71, featuring a high estimate of $1,190.00 and a low of $675.00. This average target implies a notable upside potential of 18.10% from Eli Lilly's current stock price of $819.36. Investors seeking deeper insights into these projections can explore more details on the Eli Lilly and Co (LLY) Forecast page.
Brokerage Firms' Recommendations
Reflecting broad analyst optimism, the consensus recommendation from 29 brokerage firms gives Eli Lilly and Co (LLY, Financial) an average brokerage recommendation of 2.0, which equates to an "Outperform" rating. This rating is based on a scale from 1 to 5, where 1 suggests a Strong Buy and 5 indicates a Sell. Such a consensus underscores significant confidence in Eli Lilly's market performance.
Estimations from GuruFocus
According to GuruFocus estimates, the GF Value for Eli Lilly and Co (LLY, Financial) is projected at $1,199.00 within one year. This estimation suggests a remarkable upside of 46.33% from the current price of $819.36. The GF Value represents GuruFocus' calculated fair value of the stock, derived from historical trading multiples and anticipated growth trajectories. Investors can delve into more comprehensive data on the Eli Lilly and Co (LLY) Summary page.
